Ads
related to: Renal Cell Carcinoma- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- Patient Resources
Find Patient Resources
On The Official Site.
- How This Treatment Works
Search results
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $24.64 Average Target Price from Analysts
ETF DAILY NEWS· 5 days agoShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been given a consensus rating of “Buy” by the ten ratings firms that are currently covering the stock, Marketbeat ...
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Benzinga· 4 days agoDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20 TherapiesCD 70
New York State Common Retirement Fund Sells 5,141 Shares of Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 2 days agoNew York State Common Retirement Fund trimmed its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 0.5% during the 4th quarter, according to the company in ...
Retirement Systems of Alabama Sells 8,056 Shares of Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 2 days agoRetirement Systems of Alabama cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure ...
Headlands Technologies LLC Has $32,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 2 days agoHeadlands Technologies LLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 70.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,341 shares of the biotechnology ...
Short Interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Rises By 5.6%
ETF DAILY NEWS· 3 days agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 48,980,000 shares ...
Unknown risk factor linked to high rates of kidney cancer, DNA study finds
Medical Xpress· 3 days agoIn a paper published in Nature, scientists from the Mutographs Cancer Grand Challenges team, based at the Wellcome Sanger Institute, the International Agency for Research on Cancer, and a large ...
Ads
related to: Renal Cell Carcinoma